A novel, simple bioactivity assay for relaxin based on inhibition of platelet aggregation

Regulatory Peptides

Volumn 144, Issue 1-3, 2007, Pages 10-16

  Bani, Daniele ^a   Nistri, Silvia ^a   Cinci, Lorenzo ^a   Giannini, Lucia ^a   Princivalle, Marc ^b   Elliott, Lucy ^b   Bigazzi, Mario ^c   Masini, Emanuela ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Ferring Research Ltd   (United Kingdom)

^c Prosperius Institute   (Italy)

Author keywords

Bioassay; Cyclic nucleotides; Platelets; Relaxin; THP 1 cells

Indexed keywords

ADENOSINE DIPHOSPHATE; BETA ACTIN; CYCLIC AMP; CYCLIC GMP; MESSENGER RNA; NITRIC OXIDE; RECOMBINANT RELAXIN;

ARTICLE; BIOASSAY; CELL CULTURE; HORMONE ACTION; HUMAN; HUMAN CELL; MONOCYTE; NUCLEOTIDE SEQUENCE; PEPTIDE ANALYSIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

BIOLOGICAL ASSAY; CELL LINE; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PLATELET AGGREGATION; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, PEPTIDE; RELAXIN; RNA, MESSENGER;

SUS;

EID: 35648943682     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2007.05.004     Document Type: Article

References (33)

1. Bathgate R.A., Samuel C.S., Burazin T.C., Gundlach A.L., and Tregear G.W. Relaxin: new peptides, receptors and novel actions. Trends Endocrinol Metab 14 (2003) 207-213
2. Samuel C.S., Du X.J., Bathgate R.A.D., and Summers R. 'Relaxin' the stiffened heart and arteries: the therapeutic potential for relaxin in the treatment of cardiovascular disease. Pharmacol Ther 112 (2006) 529-552
3. Hudson P., John M., Crawford R., Haralambidis J., Scanlon D., Gorman J., Tregear G., Shine J., and Niall H. Relaxin gene expression in human ovaries and the predicted structure of a human preprorelaxin by analysis of cDNA clones. EMBO J 3 (1984) 2333-2339
4. Bani D. Relaxin, a pleiotropic hormone. Gen Pharmacol 28 (1997) 13-22
5. Sherwood O.D. Relaxin's physiological roles and other diverse actions. Endocr Rev 25 (2004) 205-234
6. Dschietzig T., Bartsch C., Baumann G., and Stangl K. Relaxin - a pleiotropic hormone and its emerging role for experimental and clinical therapeutics. Pharmacol Ther 112 (2006) 38-56
7. Nistri S., Bigazzi M., and Bani D. Relaxin as a cardiovascular hormone. Physiology, pathophysiology and therapeutic promises. Cardiovascular and hematological agents in medicinal chemistry. (CHA-MC) 5 (2007) 101-108
8. Hsu S.Y., Nakabayashi K., Nishi S., Kumagai J., Kudo M., Sherwood O.D., and Hsueh A.J.W. Activation of orphan receptors by the hormone relaxin. Science 295 (2002) 671-674
9. Bathgate R.A., Ivell R., Sanborn B.M., Sherwood O.D., and Summers R.J. International Union of Pharmacology LVII: recommendations for the nomenclature of receptors for relaxin family peptides. Pharmacol Rev 58 (2006) 7-31
10. Sudo S., Kumagai J., Nishi S., Layfield S., Ferraro T., Bathgate R.A.D., and Hsueh A.J.W. H3 Relaxin is a specific ligand for LGR7 and activates the receptor by interacting with both the ectodomain and the exoloop 2. J Biol Chem 278 (2003) 7855-7862
11. Liu C., Eriste E., Sutton S., Chen J., Roland B., Kuei C., Farmer N., Jornvall H., Sillard R., and Lovenberg T.W. Identification of relaxin-3/INSL7 as an endogenous ligand for the orphan G-protein-coupled receptor GPCR135. J Biol Chem 278 (2003) 50754-50764
12. Liu C., Chen J., Sutton S., Roland B., Kuei C., Farmer N., Sillard R., and Lovenberg T.W. Identification of relaxin-3/INSL7 as a ligand for GPCR142. J Biol Chem 278 (2003) 50765-50770
13. Liu C., Kuei C., Sutton S., Chen J., Bonaventure P., Wu J., Nepomuceno D., Kamme F., Tran D.T., Zhu J., Wilkinson T., Bathgate R.A.D., Eriste E., Sillard R., and Lovenberg T.W. INSL5 is a high affinity specific agonist for GPCR142 (GPR100). J Biol Chem 280 (2005) 292-300
14. Sherwood O.D., and O'Byrne E.M. Purification and characterization of porcine relaxin. Arch Biochem Biophys 60 (1974) 185-196
15. Stults J.T., Bourell J.H., Canova-Davis E., Ling V.T., Laramee G.R., Winslow J.W., Griffin P.R., Rinderknecht E., and Vandlen R.L. Structural characterization by mass spectrometry of native and recombinant human relaxin. Biomed Environ Mass Spectrom 19 (1990) 655-664
16. Bell R.J., Permezel M., MacLennan A., Hughes C., Healy D., and Brennecke S. A randomized, double-blind, placebo-controlled trial of the safety of vaginal recombinant human relaxin for cervical ripening. Obstet Gynecol 82 (1993) 328-333
17. Seibold J.R., Korn J.H., Simms R., Clements P.J., Moreland L.W., Mayes M.D., Furst D.E., Rothfield N., Steen V., Weisman M., Collier D., Wigley F.M., Merkel P.A., Csuka M.E., Hsu V., Rocco S., Erikson M., Hannigan J., Harkonen W.S., and Sanders M.E. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 132 (2000) 871-879
18. Bigazzi M., Bani D., and Bani Sacchi T. Relaxin: a possible future preventative therapy for cardiovascular disease in postmenopausal women and men?. Climacteric 4 (2001) 137-143
19. Bani D., and Bigazzi M. Clinical aspects and therapeutic perspectives of relaxin. Curr Med Chem Immunol. Endocr Metab Agents 5 (2005) 403-410
20. Samuel C.S. Relaxin: antifibrotic properties and effects in models of disease. Clin Med Res 3 (2005) 241-249
21. Bani D., Bigazzi M., Masini E., Bani G., and Bani Sacchi T. Relaxin depresses platelet aggregation: in vitro studies on isolated human and rabbit platelets. Lab Invest 73 (1995) 709-716
22. Nguyen B.T., and Dessauer C.W. Relaxin stimulates protein kinase C zeta translocation: requirement for cyclic adenosine 3′,5′-monophosphate production. Mol Endocrinol 19 (2005) 1012-1023
23. Radomski M.W., Palmer R.M., and Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun 148 (1987) 1482-1489
24. Sherwood O.D. Relaxin. In: Knobil E., and Neill J. (Eds). The physiology of reproduction. 2nd Ed. (1994), Raven Press, New York 861-1010
25. St-Louis J. Relaxin inhibition of KCl-induced uterine contractions in vitro: an alternative bioassay. Can J Physiol Pharm 59 (1981) 507-512
26. Büllesbach E.E., and Schwabe C. Mouse relaxin: synthesis and biological activity of the first relaxin with an unusual crosslinking pattern. Biochem Biophys Res Commun 196 (1993) 311-319
27. Kakouris H., Eddie L.W., and Summers R.J. Cardiac effects of relaxin in rats. Lancet 339 (1992) 1076-1078
28. Tan Y.Y., Wade J.D., Tregear G.W., and Summers R.J. Comparison of relaxin receptors in rat isolated atria and uterus by use of synthetic and native relaxin analogues. Br J Pharmacol 123 (1998) 762-770
29. Fei D.T., Gross M.C., Lofgren J.L., Mora-Worms M., and Chen A.B. Cyclic AMP response to recombinant human relaxin by cultured human endometrial cells-a specific and high throughput in vitro bioassay. Biochem Biophys Res Commun 170 (1990) 214-222
30. Kramer S.M., Gibson U.E., Fendly B.M., Mohler M.A., Drolet D.W., and Johnston P.D. Increase in cyclic AMP levels by relaxin in newborn rhesus monkey uterus cell culture. In Vitro Cell Dev Biol 26 (1990) 647-656
31. Parsell D.A., Mak J.Y., Amento E.P., and Unemori E.N. Relaxin binds to and elicits a response from cells of the human monocytic cell line, THP-1. J Biol Chem 271 (1996) 27936-27941
32. Halls M.L., Bond C.P., Sudo S., Kumagai J., Ferraro T., Layfield S.L., Bathgate R.A., and Summers R.J. Multiple binding sites revealed by interaction of relaxin family peptides with native and chimeric relaxin family peptide receptors 1 and 2 (LGR7 and LGR8). J Pharmacol Exp Ther 313 (2005) 677-687
33. Armbruster R.J., Maier I., Groen H.J., Bailer S.M., Dschietzig T., Stangl K., Echner H., Lippert T.H., Seeger H., and Voelter W. A highly sensitive homologous human relaxin ELISA. In: Tregear G.W., Ivell R., Bathgate R.A., and Wade J.D. (Eds). Relaxin 2000 (2001), Kluwer, Dordrecht, NL 273-274